Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma Meeting Abstract

  

Authors:	Al-Batran, S. E.; Wainberg, Z. A.; Muro, K.; Molena, D.; Van Cutsem, E.; Hyung, W. J.; Wyrwicz, L. S.; Moehler, M.; Herrero, F. R.; Oh, D. Y.; Omori, T.; Smyth, E. C.; Liberman, M.; Stein, A.; Bilici, M.; Serrano, O.; Heilbron, E.; Hernandorena, F.; Tabernero, J.; Janjigian, Y. Y.
Abstract Title:	Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
Meeting Title:	Ann. Oncol.
Journal Title:	Annals of Oncology
Volume:	36
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2025-07-01
Language:	English
ACCESSION:	WOS:001545624000058
DOI:	10.1016/j.annonc.2025.05.544
PROVIDER:	wos
Notes:	Meeting Abstract -- 1 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/228872